WuXi Biologics agrees to sell 51.1% stake in Bestchrom

PUBT · 1d ago
WuXi Biologics agrees to sell 51.1% stake in Bestchrom
  • WuXi Biologics entered a disposal arrangement to sell its 51.1% stake in Bestchrom to an independent third party.
  • Closing is expected by December 2026.
  • Upon completion, WuXi Biologics will exit Bestchrom fully, which will no longer be consolidated.
  • The divestment is intended to improve capital allocation, sharpening focus on WuXi Biologics’ core CRDMO operations.
  • Bestchrom supplies biopharmaceutical downstream purification solutions, including chromatography resins and columns.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.